Breast Cancer Retreat

Previous Retreats

Part 1 Diet, Exercise and Lifestyle for Breast Cancer Prevention - Jennifer Ligibel, MD



Part 2 Keynote: Rethinking our strategies for breast cancer prevention - Laura Esserman, MD, MBA



Part 3 A Panel Discussion on Effective Strategies for Building Community/Academic Partnerships for Research on Cancer Screening and Prevention



Part 4 Session III: Debate on Novel blood-based strategies for early detection

 

Date and Time: Friday, September 20, 2024 | 11:45 AM – 6:00 PM
In-person Location: Starr Center | 185 Cambridge St, Boston, MA 02114


AI-Driven Cancer Solutions: From Basic Science to Standard of Care in Breast Cancer and Beyond


TRAINEE AND JUNIOR FACULTY LUNCH
*SIGN UP REQUIRED, SEE IN PERSON REGISTRATION FORM


11:00 – 11:45 A.M.
 


Lunch with speakers and moderators
 

WELCOME

11:45 – 12:15 P.M.

Lunch and networking

12:15 – 12:20 P.M.

Welcome and introductions
Connie Lehman, MD, PhD | Professor of Radiology, Harvard Medical School; Founder and Co-Director of the Breast Imaging Research Center, Massachusetts General Hospital
Renato Umeton, PhD (virtual) | Director, AI Operations & Data Science Services, Informatics & Analytics Department, Dana-Farber Cancer Institute 

KEYNOTE ADDRESS

12:20 – 1:00 P.M.

How AI is shaping cancer care
Debra Patt, MD, PhD, MBA 
| Breast Medical Oncologist, Managing Medical Director, Executive Vice President of Policy and Strategy, Texas Oncology; Medical Director of Public Policy, The US Oncology Network; Clinical Professor at Dell Medical School, The University of Texas at Austin

1:00 – 1:15 P.M.

Discussion and Q&As
Moderated by Adam Landman, MD, MS, MIS, MHS | Chief Information Officer and SVP, Digital at Mass General Brigham; Associate Physician, Department of Emergency Medicine, Brigham and Women’s Hospital; Associate Professor of Emergency Medicine, Harvard Medical School

OPPORTUNITIES AND CHALLENGES

1:15 – 1:30 P.M.

AI in the Clinic: What are the current roadblocks?
Brian Anderson, MD CEO, Coalition for Health AI (CHAI)

1:30 – 1:45 P.M.

Foundation AI Models for Cancer Evaluation
Kun-Hsing "Kun" Yu, MD, PhD | Assistant Professor, Department of Biomedical Informatics, Harvard Medical School; Assistant Professor, Department of Pathology, Brigham and Women's Hospital; Faculty Affiliate, Harvard Data Science Initiative, Harvard University 

1:45 – 2:00 P.M.

Panel discussion and Q&As
Moderated by Eliezer Van Allen, MDAssociate Professor of Medicine, Harvard Medical School; Chief, Division of Population Sciences, Dana-Farber Cancer Institute; Institute Member, Broad Institute; Member Researcher, The Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute

2:00 – 2:15 P.M.

Break

REAL-WORLD APPLICATIONS IN BREAST CANCER: THE POWER OF IMAGES

2:15 – 2:30 P.M.

Clinical translation of AI for mammography
Bill Lotter, PhD Assistant Professor, Harvard Medical School, Dana-Farber Cancer Institute, and Brigham and Women's Hospital

2:30 – 2:45 P.M.

AI-powered pathology in breast cancer
Andy Beck, MD, PhD | CEO, PathAI

2:45 – 3:00 P.M.

Panel discussion and Q&As
Moderated by Connie Lehman, MD, PhD

REAL-WORLD APPLICATIONS ELSEWHERE: WHAT CAN WE LEARN?

3:00 – 3:15 P.M.

Artificial Intelligence in the Fight Against Pancreatic Cancer
Michael Rosenthal, MD, PhD | Attending Radiologist, Brigham and Women’s Hospital; Senior Physician, Department of Imaging, Dana-Farber Cancer Institute; Investigator, Hale Family Center for Pancreatic Cancer Research; Assistant Professor of Radiology, Harvard Medical School

3:15 – 3:30 P.M.

Clinical Applications of Artificial Intelligence in Radiation Oncology
Ray Mak, MD
Associate Professor of Radiation Oncology, Harvard Medical School; Director of Clinical Innovation, Department of Radiation Oncology and Artificial Intelligence in Medicine Program, Brigham and Women’s Hospital/Dana-Farber Cancer Institute

3:30 – 3:45 P.M.

Panel discussion and Q&As
Moderated by Christopher Manz, MD, MSHP | Assistant Professor, Harvard Medical School

3:45 – 4:00 P.M.

Break

IMPLEMENTATION OF AI

4:00 – 4:30 P.M.

Transforming Patient Care with AI: The Mayo Clinic Experience
John Halamka, MD, MS (virtual) | Dwight and Dian Diercks President, Mayo Clinic Platform

4:30 – 4:45 P.M.

Discussion and Q&As
Moderated by Jason Johnson, PhDSenior Vice President, Chief Data and Analytics Officer, Dana-Farber Cancer Institute

CONCLUSION

4:45 – 4:50 P.M.

Closing remarks
Connie Lehman, MD, PhD
Renato Umeton, PhD (virtual)

4:50 – 6:00 P.M.

Social hour

Date and Time: Friday, November 17, 2023 | 12:00 PM – 6:00 PM
In-person Location: Dana-Farber Cancer Institute, Conference Room 306/307, 450 Brookline Ave, Boston, MA 02215


Targeting Cyclin-Dependent Kinases (CDKs) in Breast Cancer


  

12:00 - 12:30 pm

Lunch and Networking

INTRODUCTION

12:30-12:40 pm

Welcome and Introductions

Antonio Giordano, MD and Geoffrey Shapiro, MD, PhD

12:40 – 1:00 pm

Overview of updated clinical data with FDA-approved agents

Erica Mayer, MD, MPH

 

1:00 - 1:10pm

Q&A

 MECHANISTIC UNDERSTANDING OF CDK4/6 INHIBITOR RESISTANCE FROM CLINICAL SAMPLES

1:10 – 1:25 pm

Development of a composite genomic signature to predict CDK4/6 inhibitor resistance in diverse patient populations

Seth Wander, MD, PhD

1:25 - 1:35 pm 

Q&A

1:35 – 1:50 pm

Translating resistance to CDK4/6i in metastatic breast cancer 

Daniel Abravanel, MD, PhD

1:50 - 2:00 pm

Q&A 

NEXT GENERATION CDK INHIBITORS IN CLINICAL DEVELOPMENT

2:00 – 2:15 pm

Overview of novel agents targeting CDKs 2, 4 and 6

Antonio Giordano, MD

2:15 - 2:25 pm

Q&A

2:25 - 2:40 pm

15 Minute Break

NEW PRECLINICAL INSIGHTS

2:40 – 2:55 pm

Shifting kinase gear in resistance to CDK4/6 inhibitionIoannis Sanidas, PhD

2:55 - 3:10 pm

Q&A
3:10 – 3:25 pmA new first-in-class agent to augment CDK4/6-inhibitionGerburg Wulf, MD, PhD
3:25 - 3:40 pmQ&A
3:40 – 3:55 pmReversing CDK6 overexpression to circumvent CDK4/6 inhibitor resistanceGeoffrey Shapiro, MD, PhD
3:55 - 4:10 pmQ&A
4:10 - 4:25 pmCDK7 inhibition in ER+ breast cancer: mechanisms of action and reversal of CDK4/6 inhibitor resistanceRinath Jeselsohn, MD
4:25 - 4:40 pmQ&A

 CDK INHIBITORS AND THE IMMUNE MICROENVIRONMENT

4:40 - 4:55 pm

Cell cycle-independent therapeutic benefits of CDK2 inhibition 

Peter Sicinski, PhD

4:55 - 5:10 pm

Q&A

WRAP UP

5:10 – 5:20 pm

Closing Comments

Geoffrey Shapiro, MD, PhD 

5:20 – 6:00 pm

Social Networking Hour

The End

  

Date and Time: Friday, October 28, 2022 | 1:00 PM – 6:00 PM
In-person Location: Dana-Farber Cancer Institute, Conference Room 1620, 450 Brookline Ave, Boston, MA 02215

We have prepared an exciting agenda with lots of time for discussion and networking and we hope that you will join us in person or virtually for this research retreat.   

2022 AGENDA


1:00-1:05Welcome and Introductions 
1:05-1:30

PDX Program in informing subsequent clinical trials

Drs. Nancy Lin Jean Zhao

1:30-2:25

ADC resistance

Drs. Leif Ellisen/Aditya Bardia

2:25-2:40Break 
2:40-3:35OrganoidsDr. Sarah Hill
3:35-3:50Break 
3:50-4:45Optimization for preclinical models for ER+ Breast Cancer Dr. Nelly Polyak
4:45-5:00Closing Comments 
5:00-6:00Social Hour